. Bibiographie-$-$-1, A. Sharma, S. Shamanna, S. Kumar, A. Wanchu et al., Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period, Lupus. févr, vol.22, issue.2, pp.216-238, 2013.

S. Jacobsen, J. Petersen, S. Ullman, P. Junker, A. Voss et al., Mortality and Causes of Death of 513 Danish Patients with Systemic Lupus Erythematosus, Scandinavian Journal of Rheumatology, vol.40, issue.2, pp.75-80, 1999.
DOI : 10.1080/030097499442522

K. Kang, S. Kwok, J. Ju, K. Park, C. Cho et al., The causes of death in Korean patients with systemic lupus erythematosus over 11 years, Lupus, vol.42, issue.9, pp.989-97, 2011.
DOI : 10.1093/rheumatology/kep062

C. Charlier, C. Henegar, O. Launay, C. Pagnoux, A. Berezné et al., Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients, Annals of the Rheumatic Diseases, vol.68, issue.5, pp.658-63, 2009.
DOI : 10.1136/ard.2008.088302

E. Borba, A. Ribeiro, P. Martin, L. Costa, L. Guedes et al., Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus, JCR: Journal of Clinical Rheumatology, vol.16, issue.3, pp.119-141, 2010.
DOI : 10.1097/RHU.0b013e3181d52ed7

V. Noël, O. Lortholary, P. Casassus, M. André, and L. Guillevin, Les infections au cours du lupus syst??mique. Facteurs de risque et pronostic chez 87 patients, La Revue de M??decine Interne, vol.19, p.420, 1998.
DOI : 10.1016/S0248-8663(98)90105-9

A. Dias, M. Couto, C. Duarte, L. Inês, A. Malcata et al., White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, 103?7. 8. van Assen S414?22. 9. HAS. Calendrier des vaccinations et recommandations vaccinales HAS 2015 [Internet]. [cité 28 juin 2015]. Disponible sur, 2009.

L. Guillevin, J. Cordier, F. Lhote, P. Cohen, B. Jarrousse et al., A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener's granulomatosis, Arthritis & Rheumatism, vol.38, issue.12, pp.2187-98, 1997.
DOI : 10.1002/art.1780401213

C. Ribi, P. Cohen, C. Pagnoux, A. Mahr, J. Arène et al., Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients, Arthritis & Rheumatism, vol.36, issue.4, pp.1186-97, 2010.
DOI : 10.1002/art.27340

Z. Amoura, P. Ravaud, E. Hachulla, R. Jouenne, and B. Combe, Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 29 mai 2015 Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry, Autoimmun Rev Terrier B Arthritis Rheum. août, vol.1462, issue.8, pp.2458-66, 2010.

H. Tony, G. Burmester, H. Schulze-koops, M. Grunke, J. Henes et al., Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome, R75. 16. Díaz-Lagares CR112. 17. Edwards CJ672?6. 18. Cervera R, pp.299-308, 2003.

S. Bernatsky, J. Boivin, L. Joseph, S. Manzi, E. Ginzler et al., Mortality in systemic lupus erythematosus, Arthritis & Rheumatism, vol.51, issue.8, pp.2550-2557, 2006.
DOI : 10.1002/art.21955

L. Guillevin, F. Lhote, B. Jarrousse, O. Fain, L. Guillevin et al., Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years Longterm followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients, 405?16. 21. Gayraud M, pp.666-75, 1992.

J. Bradley, K. Brandt, and B. Katz, Infectious complications of cyclophosphamide treatment for vasculitis, Arthritis & Rheumatism, vol.82, issue.1, pp.45-53, 1989.
DOI : 10.1002/anr.1780320108

Y. Chen, H. Yu, W. Zhang, H. Ren, X. Chen et al., Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus, 343?9. 24. Ward MM, pp.664-70, 2000.

M. Jallouli, M. Frigui, S. Marzouk, I. Mâaloul, N. Kaddour et al., Infectious complications in systemic lupus erythematosus: a series of 146 patients]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, 626?31. 26. Ruiz-Irastorza G, 2008.

C. Aguirre, K. Shea, J. Edelsberg, D. Weycker, R. Farkouh et al., Predictors of major infections in systemic lupus erythematosus Rates of pneumococcal disease in adults with chronic medical conditions, Arthritis Res Ther. Open Forum Infect Dis. mars, vol.111, issue.271, p.24, 2009.

S. Jick, E. Lieberman, M. Rahman, H. Choi, B. Godeau et al., Glucocorticoid use, other associated factors, and the risk of tuberculosis):19?26. 29 Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases, 246?51. 30. Christian Michaux. Les complications infectieuses (hors infections à pyogènes), 1994.

T. Mori, H. Kameda, H. Ogawa, A. Iizuka, N. Sekiguchi et al., Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy, J Rheumatol. juill, vol.31, issue.32, 2004.

M. Morton, S. Edmonds, A. Doherty, A. Dhaygude, M. Helbert et al., Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement, Rheumatology International, vol.5, issue.11, pp.3373-82, 2012.
DOI : 10.1007/s00296-011-2151-0

H. Chen, W. Tsai, H. Leu, H. Ho, and L. Liou, Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review, Rheumatology, vol.46, issue.3, pp.539-583, 2007.
DOI : 10.1093/rheumatology/kel343

B. Pryor, S. Bologna, L. Kahl, D. Launay, G. Kaplanski et al., Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study, 1475?82. 36. Terrier B, pp.1547-1555, 1996.

S. Jeong, H. Choi, H. Lee, S. Han, B. Chin et al., Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis, 268?74. 39, pp.416-439, 2009.

M. Heusele, P. Clerson, B. Guery, M. Lambert, D. Launay et al., Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy, e78699. 42. Mowlah I. Profil de tolérance au long cours du rituximab prescrit dans les maladies immuno-inflkammatoires. Mémoire pour l'obtention du Diplôme de formation médicale spécialisée en médecine interne, pp.799-805, 2012.

B. Jarrousse, L. Guillevin, P. Bindi, E. Hachulla, P. Leclerc et al., Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis, Clin Exp Rheumatol. déc, vol.11, issue.6, pp.615-636, 1993.

P. Pellegrino, C. Carnovale, V. Perrone, D. Salvati, M. Gentili et al., Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus, Epidemiology, vol.25, issue.1, pp.155-161, 2014.
DOI : 10.1097/EDE.0000000000000033

C. Lu, Y. Wang, J. Lai, T. Lee, H. Lin et al., A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: Safety and immunity, Vaccine, vol.29, issue.3, pp.444-50, 2011.
DOI : 10.1016/j.vaccine.2010.10.081

. Immunogenicity, J. Klippel, J. Karsh, N. Stahl, J. Decker et al., A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives, ):1068?73. 47, pp.1321-1326, 1979.

J. Guthridge, A. Cogman, J. Merrill, S. Macwana, K. Bean et al., Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity, The Journal of Rheumatology, vol.40, issue.11, pp.1875-80, 2013.
DOI : 10.3899/jrheum.130170

S. Gartner, E. Woodruff, O. Elkayam, M. Yaron, D. Caspi et al., Hepatitis B vaccination of SLE patients Proceedings of the ACR Congress Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab, 623?5. 52. Gelinck LBS, pp.1402-1405, 1996.

E. Hak, J. Nordin, F. Wei, J. Mullooly, S. Poblete et al., Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity, Arch Intern Med. 14 sept J Rheumatol. juill Battafarano DF, vol.3515827, issue.557, pp.1681-1686, 1998.

A. Flahault, J. Vaillant, J. Prinseau, A. Baglin, S. Sentinelles-participants-de-la et al., Antigen-specific antibody responses in lupus patients following immunization, Arthritis Rheum. oct, vol.41, issue.10, 1998.

M. Abu-shakra, Safety of vaccination of patients with systemic lupus erythematosus, Lupus, vol.18, issue.13
DOI : 10.1177/0961203309346507

L. Elkayam, O. Paran, D. Burke, M. Zakut, V. Ben-yitshak et al., Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies):493?6. 60 High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus):1121?7. 61. Rolland ludivine. Evaluation des pratiques de prévention anti-infectieuses chez les personnes traitées par immunosuppresseurs pour une maladie immuno, Autoimmunity. nov Arthritis Care Res. juill, vol.183865, issue.5977, p.62, 2005.

N. Basu, R. Watts, I. Bajema, B. Baslund, T. Bley et al., EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis, Annals of the Rheumatic Diseases, vol.69, issue.10
DOI : 10.1136/ard.2009.119032

L. Guillevin, O. Meyer, and J. Sibilia, Traité des maladies et syndromes systémiques. 5ème édition. Paris: Flammarion médecine-sciences, 2008.

C. Vitali, S. Bombardieri, H. Moutsopoulos, G. Balestrieri, W. Bencivelli et al., Preliminary criteria for the classification of Sj??gren's syndrome. Results of a prospective concerted action supported by the European community, Arthritis & Rheumatism, vol.10, issue.3, pp.340-347, 1993.
DOI : 10.1002/art.1780360309

M. Petri, D. Hellmann, and M. Hochberg, Validity and reliability of lupus activity measures in the routine clinic setting, J Rheumatol. janv Amezcua-Guerra LM, vol.19, issue.70, 1992.

C. Tena, Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology classification criteria for systemic lupus erythematosus in a real-life scenario):437?41. 71. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease, Arthritis Care Res. mars Lancet Lond Engl. 5 mai, vol.67335, issue.38697, pp.1078-80, 1990.

F. Davatchi, S. Abdollahi, B. Chams-davatchi, C. Shahram, F. Shams et al., The saga of diagnostic/classification criteria in Behcet's disease International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD) The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria Classification criteria of Sjögren's syndrome, ):594?605. 73338?47. 74. Goules AV, Tzioufas AG, Moutsopoulos HM, pp.48-4942, 2014.

F. Davatchi, S. Abdollahi, B. , T. Banihashemi, A. Shahram et al., Colchicine versus placebo in Beh??et???s disease: randomized, double-blind, controlled crossover trial, Modern Rheumatology, vol.43, issue.5, pp.542-551, 2009.
DOI : 10.3109/s10165-009-0200-2

M. Melikoglu, I. Fresko, C. Mat, Y. Ozyazgan, F. Gogus et al., Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study, J Rheumatol. janv, vol.32, issue.1, pp.98-105, 2005.

G. Hatemi, A. Silman, D. Bang, B. Bodaghi, A. Chamberlain et al., Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1528-1562, 2009.
DOI : 10.1136/ard.2008.087957

S. Shiboski, C. Shiboski, L. Criswell, A. Baer, S. Challacombe et al., American College of Rheumatology classification criteria for Sjögren's syndrome: a datadriven , expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort, 475?87. 79. Devauchelle-Pensec V, pp.233-275, 2012.

J. Gottenberg, P. Ravaud, X. Puéchal, L. Guern, V. Sibilia et al., Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sj??gren Syndrome, JAMA, vol.312, issue.3, pp.249-58, 2014.
DOI : 10.1001/jama.2014.7682

E. Lo and S. Deane, Diagnosis and classification of immune-mediated thrombocytopenia, Autoimmunity Reviews, vol.13, issue.4-5
DOI : 10.1016/j.autrev.2014.01.026

J. George, J. Wasser, C. Neunert, W. Lim, M. Crowther et al., Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the The American Society of Hematology ITP Practice Guideline Panel evidence-based practice guideline for immune thrombocytopenia Treatment practices in adults with chronic immune thrombocytopenia ? a European perspective, Ann Intern Med. 15 févr Blood. 21 avr Eur J Haematol. 1 févr, vol.12611784, issue.842, pp.319-345, 1997.

J. George, S. Mathias, R. Go, M. Guo, D. Henry et al., Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. The Lancet, 395?403. 87. Kuter DJ, 2008.

G. Cheng, M. Saleh, C. Marcher, S. Vasey, B. Mayer et al., Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura, 393?402. 89. Bussel JB, pp.2237-2284, 2007.

B. Godeau, M. Khellaf, J. Viallard, F. Dreyfus, and P. Fenaux, Anémies hémolytiques autoimmunes Protocole national de diagnostic et de soins Guide des affections longue durée HAS

M. Michel, V. Chanet, A. Dechartres, A. Morin, J. Piette et al., The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia, 3167?72. 92. Comellas-3058?63. 93. Birgens H, pp.393-402, 2009.

W. Barcellini, B. Fattizzo, A. Zaninoni, T. Radice, I. Nichele et al., Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients, Blood, vol.124, issue.19, pp.2930-2936, 2014.
DOI : 10.1182/blood-2014-06-583021

W. Wilson, A. Gharavi, T. Koike, M. Lockshin, D. Branch et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, pp.1309-1320, 1999.
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

M. Lockshin, L. Sammaritano, and S. Schwartzman, Validation of the Sapporo criteria for antiphospholipid syndrome, Arthritis & Rheumatism, vol.43, issue.2, pp.440-443, 2000.
DOI : 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N

O. Benveniste, O. Dubourg, and S. Herson, Nouvelles classifications et??physiopathologie des??myopathies inflammatoires, La Revue de M??decine Interne, vol.28, issue.9, pp.603-615, 2007.
DOI : 10.1016/j.revmed.2007.03.004

A. Amato and R. Griggs, Unicorns, dragons, polymyositis, and other mythological beasts, Neurology, vol.61, issue.3, pp.288-297, 2003.
DOI : 10.1212/WNL.61.3.288

A. Bohan and J. Peter, Polymyositis and Dermatomyositis, New England Journal of Medicine, vol.292, issue.7, pp.344-351, 1975.
DOI : 10.1056/NEJM197502132920706

M. Van-der-meulen, I. Bronner, J. Hoogendijk, H. Burger, W. Van-venrooij et al., Polymyositis, Neurology, vol.61, issue.3, pp.316-337, 2003.
DOI : 10.1212/WNL.61.3.316

C. Guezennec, M. Giaoui, J. Voignier, H. Legrand, and E. Fournier, Evolution des taux plasmatiques des LDH (lacticodeshydrog??nase), CPK (cr??atine phosphokinase) et de la myoglobine ?? l'issue d'une course de 100 km et d'un triathlon, Science & Sports, vol.1, issue.3, pp.255-63, 1986.
DOI : 10.1016/S0765-1597(86)80007-7

D. Bleecker, J. Lundberg, I. De-visser, and M. , 193rd ENMC International workshop Pathology diagnosis of idiopathic inflammatory myopathies 30 November ??? 2 December 2012, Naarden, The Netherlands, Neuromuscular Disorders, vol.23, issue.11, pp.945-51, 2012.
DOI : 10.1016/j.nmd.2013.07.007

H. Linklater, N. Pipitone, M. Rose, F. Norwood, R. Campbell et al., Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria, Clin Exp Rheumatol. oct, vol.31, issue.5, pp.767-776, 2013.

I. Targoff, F. Miller, T. Medsger, and C. Oddis, Classification criteria for the idiopathic inflammatory myopathies, Current Opinion in Rheumatology, vol.9, issue.6, pp.527-562, 1997.
DOI : 10.1097/00002281-199711000-00008

M. Dalakas and R. Hohlfeld, Polymyositis and dermatomyositis. The Lancet, pp.971-82, 2003.

J. Hoogendijk, A. Amato, B. Lecky, E. Choy, I. Lundberg et al., 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscul Disord. mai, vol.1014, issue.5, pp.337-382, 2003.

Y. Troyanov, I. Targoff, M. Payette, J. Raynauld, S. Chartier et al., Redefining Dermatomyositis, Medicine, vol.93, issue.24, pp.318-350, 2014.
DOI : 10.1097/MD.0000000000000222

URL : http://doi.org/10.1097/md.0000000000000222

Y. Troyanov, I. Targoff, J. Tremblay, J. Goulet, R. Y. Senécal et al., Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies, Medicine, vol.84, issue.4, pp.231-280, 2005.
DOI : 10.1097/01.md.0000173991.74008.b0

B. Hervier and O. Benveniste, Ph??notypes cliniques et pronostic du syndrome des antisynth??tases, La Revue de M??decine Interne, vol.35, issue.7, pp.453-60, 2014.
DOI : 10.1016/j.revmed.2013.09.003

T. Kurita, S. Yasuda, K. Oba, T. Odani, M. Kono et al., The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis, Rheumatology, vol.54, issue.1, pp.39-44, 2015.
DOI : 10.1093/rheumatology/keu166

N. Miyasaka, M. Hara, T. Koike, E. Saito, M. Yamada et al., Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial, Modern Rheumatology, vol.44, issue.3, pp.382-93, 2012.
DOI : 10.1056/NEJM199312303292704

H. Alexanderson, L. Munters, M. Dastmalchi, I. Loell, M. Heimbürger et al., Resistive Home Exercise in Patients with Recent-onset Polymyositis and Dermatomyositis -- A Randomized Controlled Single-blinded Study with a 2-year Followup, The Journal of Rheumatology, vol.41, issue.6, pp.1124-1156, 2014.
DOI : 10.3899/jrheum.131145

C. Oddis, L. Rider, A. Reed, R. N. Brunner, H. Koneru et al., International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies, Arthritis & Rheumatism, vol.38, issue.9, pp.2607-2622, 2005.
DOI : 10.1002/art.21291

S. Jouneau, B. Hervier, E. Jutant, O. Decaux, M. Kambouchner et al., Les manifestations pulmonaires du syndrome des antisynth??tases, Revue des Maladies Respiratoires, vol.32, issue.6, pp.618-646, 2015.
DOI : 10.1016/j.rmr.2014.07.013

URL : http://dx.doi.org/10.1016/j.rmr.2014.07.013

M. Dugar, S. Cox, V. Limaye, P. Blumbergs, and P. Roberts-thomson, Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies, Internal Medicine Journal, vol.70, issue.9, pp.674-683, 2011.
DOI : 10.1111/j.1445-5994.2010.02164.x

L. Essaadouni, Les crit??res diagnostiques de la maladie de Takayasu, La Revue de M??decine Interne, vol.30, pp.255-262, 2009.
DOI : 10.1016/j.revmed.2009.09.005

B. Sharma, S. Jain, S. Suri, and F. Numano, Diagnostic criteria for Takayasu arteritis, International Journal of Cardiology, vol.54, pp.127-160, 1996.
DOI : 10.1016/0167-5273(96)02647-2

M. Walter, R. Melzer, C. Schindler, J. Müller-brand, A. Tyndall et al., The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease, European Journal of Nuclear Medicine and Molecular Imaging, vol.43, issue.Suppl 2, pp.674-81, 2005.
DOI : 10.1007/s00259-004-1757-9

A. Mekinian, A. Néel, J. Sibilia, P. Cohen, J. Connault et al., Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study, Rheumatology, vol.51, issue.5, pp.882-888, 2012.
DOI : 10.1093/rheumatology/ker380

É. Pillebout and J. Verine, Purpura rhumato??de de l???adulte, La Revue de M??decine Interne, vol.35, issue.6, pp.372-81, 2014.
DOI : 10.1016/j.revmed.2013.12.004

J. Mills, B. Michel, D. Bloch, L. Calabrese, G. Hunder et al., The American College of Rheumatology 1990 criteria for the classification of henoch-sch??nlein purpura, Arthritis & Rheumatism, vol.33, issue.8, pp.1114-1135, 1990.
DOI : 10.1002/art.1780330809

E. Printo, PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis, 2008.

A. Masi, G. Hunder, J. Lie, B. Michel, D. Bloch et al., The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis), Arthritis & Rheumatism, vol.56, issue.8, pp.1094-100, 1990.
DOI : 10.1002/art.1780330806

R. Leavitt, A. Fauci, D. Bloch, B. Michel, G. Hunder et al., The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis, Arthritis & Rheumatism, vol.19, issue.8, pp.1101-1108, 1990.
DOI : 10.1002/art.1780330807

I. Bruce and A. Bell, A comparison of two nomenclature systems for primary systemic vasculitis, Rheumatology, vol.36, issue.4, pp.453-461, 1997.
DOI : 10.1093/rheumatology/36.4.453

J. Jennette, R. Falk, K. Andrassy, P. Bacon, J. Churg et al., Nomenclature of Systemic Vasculitides, Arthritis & Rheumatism, vol.91, issue.2, pp.187-92, 1994.
DOI : 10.1002/art.1780370206

J. Jennette, R. Falk, P. Bacon, N. Basu, M. Cid et al., 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, pp.1-11, 2012.
DOI : 10.1002/art.37715

C. Kallenberg, The diagnosis and classification of microscopic polyangiitis, Journal of Autoimmunity, vol.48, issue.49, pp.48-4990, 2014.
DOI : 10.1016/j.jaut.2014.01.023

B. Hellmich, O. Flossmann, W. Gross, P. Bacon, J. Cohen-tervaert et al., EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis, Annals of the Rheumatic Diseases, vol.66, issue.5, pp.605-622, 2007.
DOI : 10.1136/ard.2006.062711

J. Thiel, F. Hässler, U. Salzer, R. Voll, and N. Venhoff, Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), Arthritis Research & Therapy, vol.15, issue.5, p.133, 2013.
DOI : 10.1016/j.jaci.2010.02.026

L. Guillevin, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaître et al., Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis, New England Journal of Medicine, vol.371, issue.19, pp.1771-80, 2014.
DOI : 10.1056/NEJMoa1404231

URL : https://hal.archives-ouvertes.fr/hal-01116525

V. Martinez, P. Cohen, C. Pagnoux, S. Vinzio, A. Mahr et al., Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients, Arthritis & Rheumatism, vol.345, issue.1, pp.308-325, 2008.
DOI : 10.1002/art.23147

J. Brouet, J. Clauvel, F. Danon, M. Klein, and M. Seligmann, Biologic and clinical significance of cryoglobulins, The American Journal of Medicine, vol.57, issue.5, pp.775-88, 1974.
DOI : 10.1016/0002-9343(74)90852-3

S. Vita, F. Soldano, M. Isola, G. Monti, A. Gabrielli et al., Preliminary classification criteria for the cryoglobulinaemic vasculitis, Annals of the Rheumatic Diseases, vol.70, issue.7, pp.1183-90, 2011.
DOI : 10.1136/ard.2011.150755

L. Quartuccio, M. Isola, L. Corazza, M. Ramos-casals, S. Retamozo et al., Validation of the classification criteria for cryoglobulinaemic vasculitis, Rheumatology, vol.53, issue.12, pp.2209-2222, 2014.
DOI : 10.1093/rheumatology/keu271

R. Deremee, T. Mcdonald, E. Harrison, and D. Coles, Wegener's granulomatosis. Anatomic correlates, a proposed classification, Mayo Clin Proc. déc, vol.51, issue.12, pp.777-81, 1976.

D. Altman and P. Royston, What do we mean by validating a prognostic model?, Statistics in Medicine, vol.130, issue.4, pp.453-73, 2000.
DOI : 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5

R. Seror, P. Ravaud, S. Bowman, G. Baron, A. Tzioufas et al., EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.1103-1112, 2010.
DOI : 10.1136/ard.2009.110619

D. Isenberg, International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease, Rheumatology, vol.43, issue.1, pp.49-54, 2004.
DOI : 10.1093/rheumatology/keg427

F. Miller, L. Rider, Y. Chung, R. Cooper, K. Danko et al., Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies, Rheumatology, vol.40, issue.11, pp.1262-73, 2001.
DOI : 10.1093/rheumatology/40.11.1262

Z. Touma, D. Gladman, D. Ibañez, S. Taghavi-zadeh, and M. Urowitz, Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials, The Journal of Rheumatology, vol.38, issue.11, pp.2395-2404, 2011.
DOI : 10.3899/jrheum.110550

H. Vanquaethem, L. Couzi, E. Lazaro, L. Raffray, C. Dieval et al., Le rituximab dans l???indication ????n??phropathie lupique??????: ??tude r??trospective du CHU de Bordeaux, France, La Revue de M??decine Interne, vol.33, issue.2, pp.83-87, 2012.
DOI : 10.1016/j.revmed.2012.10.117

M. Gerfaud-valentin, M. Mahévas, L. Terriou, O. Lambotte, S. Cheze et al., Caract??ristiques et modalit??s ??volutives du purpura thrombop??nique idiopathique multir??fractaire en 2014??: analyse de 26??observations, La Revue de M??decine Interne, vol.35, issue.2, pp.86-93, 2014.
DOI : 10.1016/j.revmed.2014.10.138

S. Brah, L. Chiche, E. Bernit, G. Thomas, M. Ebbo et al., Utilisation r??p??t??e du rituximab dans le traitement des thrombop??nies auto-immunes??: ??tude monocentrique sur 12??cas, La Revue de M??decine Interne, vol.32, p.50, 2011.
DOI : 10.1016/j.revmed.2011.03.030

J. Fitzgerald and J. Grossman, Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients, Lupus, vol.31, issue.8, pp.638-682, 1999.
DOI : 10.1191/096120399680411443

M. Petri, M. Kim, K. Kalunian, J. Grossman, B. Hahn et al., Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus, New England Journal of Medicine, vol.353, issue.24, pp.2550-2558, 2005.
DOI : 10.1056/NEJMoa051135

D. Gladman, D. Ibañez, and M. Urowitz, Systemic lupus erythematosus disease activity index 2000, J Rheumatol. févr, vol.29, issue.2, pp.288-91, 2002.

D. Isenberg and C. Gordon, From BILAG to BLIPS???disease activity assessment in lupus past, present and future, Lupus, vol.9, issue.9, pp.651-655, 2000.
DOI : 10.1191/096120300672904669

M. Petri, J. Buyon, and M. Kim, Classification and definition of major flares in SLE clinical trials, Lupus, vol.26, issue.2, pp.685-91, 1999.
DOI : 10.1191/096120399680411281

D. Isenberg, A. Rahman, E. Allen, V. Farewell, M. Akil et al., BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus, Rheumatology, vol.44, issue.7, pp.902-908, 2004.
DOI : 10.1093/rheumatology/keh624

C. Gordon, Definition and treatment of lupus flares measured by the BILAG index, Rheumatology, vol.42, issue.11, pp.1372-1381, 2003.
DOI : 10.1093/rheumatology/keg382

C. Yee, D. Isenberg, A. Prabu, K. Sokoll, L. Teh et al., BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000, Annals of the Rheumatic Diseases, vol.67, issue.6, pp.873-879, 2008.
DOI : 10.1136/ard.2007.070847

C. Yee, V. Farewell, D. Isenberg, B. Griffiths, L. Teh et al., The BILAG-2004 index is sensitive to change for assessment of SLE disease activity, Rheumatology, vol.48, issue.6, pp.691-696, 2009.
DOI : 10.1093/rheumatology/kep064

J. Mikdashi and O. Nived, Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research, Arthritis Research & Therapy, vol.20, issue.1, p.183, 2015.
DOI : 10.1186/s13075-015-0702-6

K. Luijten, J. Tekstra, J. Bijlsma, and M. Bijl, The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment, Autoimmunity Reviews, vol.11, issue.5, pp.326-335, 2012.
DOI : 10.1016/j.autrev.2011.06.011

C. Vitali, W. Bencivelli, D. Isenberg, J. Smolen, M. Snaith et al., Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE, Clin Exp Rheumatol. oct, vol.10, issue.5, pp.541-548, 1992.

M. Mosca, W. Bencivelli, C. Vitali, P. Carrai, R. Neri et al., The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus, Lupus, vol.1, issue.1, pp.445-50, 2000.
DOI : 10.1191/096120300678828640

E. Hay, P. Bacon, C. Gordon, D. Isenberg, P. Maddison et al., The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus, Q J Med. juill, vol.86, issue.7, pp.447-58, 1993.

M. Baltaci, A review on disease activity scores in Behçet's disease (BD), Arthritis Research & Therapy, vol.5, issue.Suppl 2, p.7, 2003.
DOI : 10.1186/ar982

B. Bhakta, P. Brennan, T. James, M. Chamberlain, B. Noble et al., Behcet's disease: evaluation of a new instrument to measure clinical activity, Rheumatology, vol.38, issue.8, pp.728-761, 1999.
DOI : 10.1093/rheumatology/38.8.728

G. Lawton, B. Bhakta, M. Chamberlain, and A. Tennant, The Behcet's Disease Activity Index, Rheumatology, vol.43, issue.1, pp.73-81, 2004.
DOI : 10.1093/rheumatology/keg453

G. Hatemi, P. Merkel, V. Hamuryudan, M. Boers, H. Direskeneli et al., Outcome Measures Used in Clinical Trials for Behcet Syndrome: A Systematic Review, The Journal of Rheumatology, vol.41, issue.3, pp.599-612, 2014.
DOI : 10.3899/jrheum.131249

G. Hatemi, P. Merkel, V. Hamuryudan, M. Boers, H. Direskeneli et al., Outcome Measures Used in Clinical Trials for Behcet Syndrome: A Systematic Review, The Journal of Rheumatology, vol.41, issue.3, pp.599-612, 2014.
DOI : 10.3899/jrheum.131249

A. Campar and D. Isenberg, Primary Sj??gren???s syndrome activity and damage indices comparison, European Journal of Clinical Investigation, vol.44, issue.31 Suppl, pp.636-680, 2010.
DOI : 10.1111/j.1365-2362.2010.02303.x

G. Hernández-molina and T. Sánchez-hernández, Clinimetric methods in Sj??gren's syndrome, Seminars in Arthritis and Rheumatism, vol.42, issue.6, pp.627-666, 2013.
DOI : 10.1016/j.semarthrit.2012.09.008

S. Bowman, N. Sutcliffe, D. Isenberg, F. Goldblatt, M. Adler et al., Sjogren's Systemic Clinical Activity Index (SCAI) a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome, Rheumatology, vol.46, issue.12, pp.1845-51, 2007.
DOI : 10.1093/rheumatology/kem280

R. Seror, H. Bootsma, S. Bowman, T. Dörner, J. Gottenberg et al., Outcome measures for primary Sj??gren???s syndrome, Journal of Autoimmunity, vol.39, issue.1-2, pp.97-102, 2012.
DOI : 10.1016/j.jaut.2012.01.013

C. Vitali, G. Palombi, C. Baldini, M. Benucci, S. Bombardieri et al., Sj??gren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sj??gren's syndrome, derived from an analysis of a cohort of Italian patients, Arthritis & Rheumatism, vol.2, issue.7, pp.2223-2254, 2007.
DOI : 10.1002/art.22658

R. Seror, J. Gottenberg, V. Devauchelle-pensec, J. Dubost, L. Guern et al., European League Against Rheumatism Sj??gren's Syndrome Disease Activity Index and European League Against Rheumatism Sj??gren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sj??gren's Syndrome Patients, Arthritis Care & Research, vol.63, issue.8, pp.1358-64, 2013.
DOI : 10.1002/acr.21991

R. Seror, M. X. Bowman, S. Baron, G. Gottenberg, J. Bootsma et al., Accurate detection of changes in disease activity in primary Sj??gren's syndrome by the European League Against Rheumatism Sj??gren's Syndrome Disease Activity Index, Arthritis Care & Research, vol.29, issue.4, pp.551-559, 2010.
DOI : 10.1002/acr.20173

M. Ramos-casals, P. Brito-zerón, R. Solans, M. Camps, A. Casanovas et al., Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry), Rheumatology, vol.53, issue.2, pp.321-352, 2014.
DOI : 10.1093/rheumatology/ket349

H. Rizvi, T. Butler, M. Calaminici, I. Doobaree, R. Nandigam et al., United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings, British Journal of Haematology, vol.90, issue.4, pp.590-594, 2015.
DOI : 10.1111/bjh.13330

F. Rodeghiero, R. Stasi, T. Gernsheimer, M. Michel, D. Provan et al., Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, vol.113, issue.11, pp.2386-93, 2009.
DOI : 10.1182/blood-2008-07-162503

K. Lechner and U. Jäger, How I treat autoimmune hemolytic anemias in adults, Blood, vol.116, issue.11, pp.1831-1839, 2010.
DOI : 10.1182/blood-2010-03-259325

O. Fain, B. Bonnotte, M. Ruivard, J. Durand, and E. Rosenthal, purpura thombopenique immunologique de l'enfant et d l'adulte Protocole national de diagnostic et de soins Guide des affections longue durée HAS. oct, 2009.

G. Buchanan, Bleeding Signs in Children With Idiopathic Thrombocytopenic Purpura, Journal of Pediatric Hematology/Oncology, vol.25, issue.Supplement 1, pp.42-48, 2003.
DOI : 10.1097/00043426-200312001-00010

V. Kretschmer, B. Huss, S. Weber, S. Bewarder, T. Schulzki et al., Determination of bleeding risk in thrombocytopenic patients with platelet transfusion therapy

L. Page, B. Psaila, D. Provan, M. Hamilton, J. Jenkins et al., The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP, British Journal of Haematology, vol.35, issue.Suppl. 1, pp.245-253, 2007.
DOI : 10.1111/j.1365-2141.2007.06635.x

F. Kendall, E. Mccreary, and P. Provance, Muscles: Testing and function. 4ème édition. Williams and Wilkins, 1993.

L. Rider, D. Koziol, E. Giannini, M. Jain, M. Smith et al., Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies, Arthritis Care & Research, vol.10, issue.4, pp.465-72, 2010.
DOI : 10.1002/acr.20035

D. Isenberg, A. E. Farewell, V. Ehrenstein, M. Hanna, M. Lundberg et al., International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease, Rheumatology, vol.43, issue.1, pp.49-54, 2004.
DOI : 10.1093/rheumatology/keg427

L. Rider, E. Giannini, M. Harris-love, G. Joe, D. Isenberg et al., Defining Clinical Improvement in Adult and Juvenile Myositis, J Rheumatol. 3 janv, vol.30, issue.3, pp.603-620, 2003.

A. Tournadre, Prise en charge thérapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies nécrosantes auto-immunes. Rev Médecine Interne, juill, vol.35, issue.7, pp.466-71, 2014.

C. Oddis, L. Rider, A. Reed, R. N. Brunner, H. Koneru et al., International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies, Arthritis & Rheumatism, vol.38, issue.9, pp.2607-2622, 2005.
DOI : 10.1002/art.21291

R. Luqmani, P. Bacon, R. Moots, B. Janssen, A. Pall et al., Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis, QJM Mon J Assoc Physicians. nov, vol.87, issue.11, pp.671-679, 1994.

P. Merkel, P. Seo, P. Aries, T. Neogi, A. Villa-forte et al., Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis, J Rheumatol, vol.32, issue.12, pp.2488-95, 2005.

K. De-groot, W. Gross, K. Herlyn, and E. Reinhold-keller, Development and validation of a disease extent index for Wegener's granulomatosis, Clin Nephrol. janv, vol.55, issue.1, pp.31-39, 2001.

C. Mukhtyar, R. Lee, D. Brown, D. Carruthers, B. Dasgupta et al., Modification and validation of the Birmingham Vasculitis Activity Score (version 3), Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1827-1859, 2009.
DOI : 10.1136/ard.2008.101279

R. Suppiah, C. Mukhtyar, O. Flossmann, F. Alberici, B. Baslund et al., A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis, Rheumatology, vol.50, issue.5, pp.899-905, 2011.
DOI : 10.1093/rheumatology/keq400

M. Walsh, P. Merkel, C. Peh, W. Szpirt, L. Guillevin et al., Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial, Trials, vol.14, issue.1, p.73, 2013.
DOI : 10.1016/j.ymgme.2008.10.003

L. Azar, J. Springer, C. Langford, and G. Hoffman, Rituximab With or Without a Conventional Maintenance Agent in the Treatment of Relapsing Granulomatosis With Polyangiitis (Wegener's): A Retrospective Single-Center Study, Arthritis & Rheumatology, vol.64, issue.Suppl, pp.2862-70, 2014.
DOI : 10.1002/art.38744

L. Guillevin, F. Lhote, M. Gayraud, P. Cohen, B. Jarrousse et al., Prognostic Factors in Polyarteritis Nodosa and Churg-Strauss Syndrome A Prospective Study in 342 Patients, Medicine, vol.75, issue.1, pp.17-28, 1996.
DOI : 10.1097/00005792-199601000-00003

O. Aumaître, D. Chauveau, J. Cordier, P. Gobert, L. Guillevin et al., vascularites nécrosantes systémiques Protocole national de diagnostic et de soins Guide des affections longue durée HAS, 2007.

L. Guillevin, P. Cohen, A. Mahr, J. Arène, L. Mouthon et al., Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients, Arthritis Care & Research, vol.112, issue.Suppl 9, pp.93-100, 2003.
DOI : 10.1002/art.10922

M. Samson, X. Puéchal, H. Devilliers, C. Ribi, P. Cohen et al., Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors, Autoimmunity Reviews, vol.13, issue.9, pp.945-53, 2014.
DOI : 10.1016/j.autrev.2014.08.002

L. Guillevin, C. Pagnoux, R. Seror, A. Mahr, L. Mouthon et al., The Five-Factor Score Revisited, Medicine, vol.90, issue.1, pp.19-27, 2011.
DOI : 10.1097/MD.0b013e318205a4c6

Q. Whiting-o-'keefe, J. Stone, and D. Hellmann, Validity of a vasculitis activity index for systemic necrotizing vasculitis, Arthritis & Rheumatism, vol.9, issue.11, pp.2365-71, 1999.
DOI : 10.1002/1529-0131(199911)42:11<2365::AID-ANR15>3.0.CO;2-M

P. Merkel, D. Cuthbertson, B. Hellmich, G. Hoffman, J. D. Kallenberg et al., Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.103-109, 2009.
DOI : 10.1136/ard.2008.097758

E. Sato, F. Hatta, M. Levy-neto, and S. Fernandes, Demographic, clinical, and angiographic data of patients with Takayasu arteritis in Brazil, International Journal of Cardiology, vol.66, 1998.
DOI : 10.1016/S0167-5273(98)00152-1

M. Sivakumar, R. Misra, and P. Bacon, Group for the I. Op14. the Indian Perspective of Takayasu Arteritis and Development of a Disease Extent Index (dei.tak) to Assess Takayasu Arteritis, Rheumatology. 7 janv, vol.44, issue.3, pp.6-7, 2005.

G. Kerr, C. Hallahan, J. Giordano, R. Leavitt, A. Fauci et al., Takayasu Arteritis, Annals of Internal Medicine, vol.120, issue.11, pp.919-948, 1994.
DOI : 10.7326/0003-4819-120-11-199406010-00004

Y. Xia, J. Mao, Y. Chen, D. Wang, L. Cao et al., Clinical outcomes in children with Henoch???Sch??nlein purpura nephritis grade IIIa or IIIb, Pediatric Nephrology, vol.49, issue.7, pp.1083-1091, 2011.
DOI : 10.1007/s00467-011-1834-9

J. Bergstein, J. Leiser, and S. Andreoli, Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy, Clin Nephrol. janv, vol.49, issue.1, pp.9-14, 1998.

J. Dudley, G. Smith, A. Llewelyn-edwards, K. Bayliss, K. Pike et al., Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP), Archives of Disease in Childhood, vol.94, issue.10, pp.756-63, 2013.
DOI : 10.1136/archdischild-2013-303642

J. Flynn, W. Smoyer, T. Bunchman, D. Kershaw, and A. Sedman, Treatment of Henoch-Sch??nlein Purpura Glomerulonephritis in Children with High-Dose Corticosteroids plus Oral Cyclophosphamide, American Journal of Nephrology, vol.21, issue.2, pp.128-161, 2001.
DOI : 10.1159/000046235

D. Ding, H. Yan, and X. Zhen, Effects of Chinese herbs in children with Henoch-Schonlein purpura nephritis: a randomized controlled trial, Journal of Traditional Chinese Medicine, vol.34, issue.1, pp.15-22, 2014.
DOI : 10.1016/S0254-6272(14)60048-0

O. Jauhola, J. Ronkainen, H. Autio-harmainen, O. Koskimies, M. Ala-houhala et al., Cyclosporine A vs. methylprednisolone for Henoch???Sch??nlein nephritis: a randomized trial, Pediatric Nephrology, vol.40, issue.12, pp.2159-66, 2011.
DOI : 10.1007/s00467-011-1919-5

J. Ronkainen, H. Autio-harmainen, and M. Nuutinen, Cyclosporin A for the treatment of severe Henoch-Sch???nlein glomerulonephritis, Pediatric Nephrology, vol.18, issue.11, pp.1138-1180, 2003.
DOI : 10.1007/s00467-003-1245-7

O. Jauhola, J. Ronkainen, O. Koskimies, M. Ala-houhala, P. Arikoski et al., Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study, Archives of Disease in Childhood, vol.95, issue.11, pp.871-877, 2010.
DOI : 10.1136/adc.2009.167874

J. Ronkainen, O. Koskimies, M. Ala-houhala, M. Antikainen, J. Merenmies et al., Early prednisone therapy in Henoch-Sch??nlein purpura: A randomized, double-blind, placebo-controlled trial, The Journal of Pediatrics, vol.149, issue.2, pp.241-248, 2006.
DOI : 10.1016/j.jpeds.2006.03.024

R. Seror, H. Bootsma, A. Saraux, S. Bowman, E. Theander et al., Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) Ann Rheum Dis, 2014.

M. Liang, S. Socher, M. Larson, and P. Schur, Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus, Arthritis & Rheumatism, vol.28, issue.9, pp.1107-1125, 1989.
DOI : 10.1002/anr.1780320909

G. Norman and K. Eva, Diagnostic error and clinical reasoning, Medical Education, vol.41, issue.1, pp.94-100, 2010.
DOI : 10.1111/j.1365-2923.2009.03507.x

D. Guzmán and J. , Diagnostic reasoning in neurology An analysis of the more frequent errors], Neurol Barc Spain. déc, vol.18, issue.2, pp.3-10, 2003.

K. Eva and G. Norman, Heuristics and biases - a biased perspective on clinical reasoning, Medical Education, vol.74, issue.7, pp.870-872, 2005.
DOI : 10.1207/S1532690XCI1704_3

Y. Auxéméry, De la subjectivité sociétale d'un déni de la subjectivité individuelle à la perception subjective des diagnostics en pratique clinique : la possibilité partielle d'un diagnostic standardisé de cette perception

M. Nendaz, Éducation et qualité de la décision médicale : un lien fondé sur des preuves existe-t-il ? Rev Médecine Interne, juill, vol.32, issue.7, pp.436-478, 2011.

P. Croskerry and G. Norman, Overconfidence in Clinical Decision Making, The American Journal of Medicine, vol.121, issue.5, pp.24-33, 2008.
DOI : 10.1016/j.amjmed.2008.02.001

S. Cattan, Le praticien enrichit-il sa compétence en s'ouvrant à sa propre subjectivité ? Médecine Palliat Soins Support -Accompagnement -Éthique, avr, vol.7, issue.2, pp.98-103, 2008.

B. Reilly and A. Evans, Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions, Annals of Internal Medicine, vol.144, issue.3, pp.201-210, 2006.
DOI : 10.7326/0003-4819-144-3-200602070-00009

G. Bachelard, . Le-nouvel-esprit, C. Robertson, J. Myers, S. Rose et al., Disponible sur: http://data.over-blog-kiwi.com/0 A Randomized Study of How Physicians Interpret Research Funding Disclosures, N Engl J Med, vol.841743367, issue.12, pp.1119-1146, 1968.

L. Fardet, T. Blanchon, A. Perdoncini-roux, A. Kettaneh, K. Tiev et al., Perception par les m??decins internistes de la fr??quence et de la g??ne induite par les effets ind??sirables d???une corticoth??rapie syst??mique prolong??e, La Revue de M??decine Interne, vol.30, issue.2, pp.113-121, 2009.
DOI : 10.1016/j.revmed.2008.08.004

P. Godard, D. Huas, B. Sohier, C. Pribil, and I. Boucot, Asthma control in general practice: a cross-sectional survey of 16,580 patients]. Presse Médicale Paris Fr, 1983.

C. Neville, A. Clarke, L. Joseph, P. Belisle, D. Ferland et al., Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity, J Rheumatol. mars, vol.27, issue.3, pp.675-684, 2000.

S. Persell, N. Dolan, E. Friesema, J. Thompson, D. Kaiser et al., Frequency of Inappropriate Medical Exceptions to Quality Measures, Annals of Internal Medicine, vol.152, issue.4, pp.225-256, 2010.
DOI : 10.7326/0003-4819-152-4-201002160-00007

E. Kiechle, S. Bailey, L. Hedlund, A. Viera, and S. Sheridan, Different Measures, Different Outcomes? A Systematic Review of Performance-Based versus Self-Reported Measures of Health Literacy and Numeracy, Journal of General Internal Medicine, vol.27, issue.1, 2015.
DOI : 10.1007/s11606-015-3288-4

J. Raude, La perception du risque': Théories et données empiriques, Rev Sci Soc, issue.38, pp.20-29, 2007.

M. Fleming, R. Flin, K. Mearns, and R. Gordon, Risk perceptions of offshore workers on UK oil and gas platforms. Risk Anal Off Publ Soc Risk Anal, févr, vol.18, issue.1, pp.103-113, 1998.

F. Scarnato, M. Mallaret, J. Croizé, D. Kouabenan, M. Dubois et al., Abstract, Infection Control & Hospital Epidemiology, vol.41, issue.06, pp.456-464, 2003.
DOI : 10.2165/00002512-199710030-00003

S. Mbaye and D. Kouabenan, Effects of the feeling of invulnerability and the feeling of control on motivation to participate in experience-based analysis, by type of risk, Accident Analysis & Prevention, vol.51, pp.310-317, 2013.
DOI : 10.1016/j.aap.2012.11.026

S. Has, C. , S. Sfr, C. Snfmi, S. et al., Recommandations concernant la prise en charge thérapeutique et suivi des Spondylarthrite Disponible sur: http://www.has-sante.fr/portail Polyarthrite rhumatoide Recommandations prise en charge initiale [Internet], Disponible sur, 2007.

T. Manser and S. Foster, Effective handover communication: An overview of research and improvement efforts, Best Practice & Research Clinical Anaesthesiology, vol.25, issue.2, pp.181-91, 2011.
DOI : 10.1016/j.bpa.2011.02.006

K. Bilimoria, D. Hoyt, and F. Lewis, Making the Case for Investigating Flexibility in Duty Hour Limits for Surgical Residents, JAMA Surgery, vol.150, issue.6, pp.503-507, 2015.
DOI : 10.1001/jamasurg.2015.0239

A. Francke, M. Smit, A. De-veer, and P. Mistiaen, Factors influencing the implementation of clinical guidelines for health care professionals: A systematic meta-review, BMC Medical Informatics and Decision Making, vol.115, issue.Suppl 2
DOI : 10.1111/j.1600-0447.2007.01016.x

J. Carthey, S. Walker, V. Deelchand, C. Vincent, and W. Griffiths, Breaking the rules: understanding non-compliance with policies and guidelines, BMJ, vol.343, issue.sep13 3, p.5283, 2011.
DOI : 10.1136/bmj.d5283

G. Canguilhem and . Le-normal-et-le-pathologique, Deuxième édition 1950 Quadrige/ Puf, 2006.